Professional Marketing briefs

Abbott announced that it will cut 1,900 positions in a restructuring exercise intended to streamline commercial and manufacturing operations. Sales jobs are one of the target areas for the cuts, according to Scott Stoffel, and Abbott spokesperson. The cost-cutting measures will take place “primarily in the US,” said Stoffel. Miles White, chairman and CEO at Abbott, cited European pricing pressures and a regulatory environment that “says no more than it says yes,” as reasons for the cuts.

Aqua Pharmaceuticals appointed Ted White to VP, sales. White's responsibilities include managing Aqua's “rapidly growing sales force,” according to a company announcement. White joins Aqua from Novartis, where he worked as managing director. Aqua is a specialty pharma focused on dermatology products.

Clinical Data will launch Viibryd, a depression medication, during the second quarter of 2011. The brand received FDA approval on January 21, and 150 sales reps will target psychiatrists and high-prescribing primary care physicians at launch, Drew Fromkin, CEO and president at Clinical Data, told MM&M. Clinical Data reps will “more likely…focus on the specialty psychiatry side, and hope to expand through other relationships on the primary care side,” said Fromkin.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.